19,354 Shares in Thermo Fisher Scientific Inc. $TMO Bought by Grandfield & Dodd LLC

Key Points

• Grandfield & Dodd LLC acquired 19,354 shares of Thermo Fisher Scientific during the second quarter, valued at approximately $9.7 million. Institutional investors collectively own 89.23% of the company.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $619.41. Thermo Fisher recently exceeded quarterly earnings and revenue expectations, reporting $6.03 in EPS and $11.99 billion in revenue.
• Thermo Fisher shares opened at $590, while insiders have sold 52,053 shares worth about $30.6 million over the past three months. The company also declared a quarterly dividend of $0.47 per share, representing a 0.3% yield.

Grandfield & Dodd LLC acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 19,354 shares of the medical research company's stock, valued at approximately $9,704,000.

Several other hedge funds have also recently modified their holdings of TMO. Auxano Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $212,000. Argyle Capital Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $361,000. MidFirst Bank acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth approximately $1,454,000. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth approximately $15,501,867,000. Finally, Pallas Capital Advisors LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at $5,197,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research note on Friday, April 24th. Barclays boosted their price target on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, July 14th. Finally, Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares of the company's stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 52,053 shares of company stock worth $30,643,589. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 0.8%

Shares of TMO opened at $590.00 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a fifty day simple moving average of $533.64 and a two-hundred day simple moving average of $508.36. The company has a market capitalization of $218.15 billion, a PE ratio of 31.74, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same quarter in the previous year, the company posted $4.28 EPS. The company's revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source